JPH0126677B2 - - Google Patents
Info
- Publication number
- JPH0126677B2 JPH0126677B2 JP61093855A JP9385586A JPH0126677B2 JP H0126677 B2 JPH0126677 B2 JP H0126677B2 JP 61093855 A JP61093855 A JP 61093855A JP 9385586 A JP9385586 A JP 9385586A JP H0126677 B2 JPH0126677 B2 JP H0126677B2
- Authority
- JP
- Japan
- Prior art keywords
- uricase
- molecular weight
- modified
- enzyme
- triazine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 108010092464 Urate Oxidase Proteins 0.000 claims description 29
- 125000003277 amino group Chemical group 0.000 claims description 8
- 125000003827 glycol group Chemical group 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 description 12
- 102000004190 Enzymes Human genes 0.000 description 12
- 230000000694 effects Effects 0.000 description 10
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 7
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 7
- 229940116269 uric acid Drugs 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 201000005569 Gout Diseases 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 229920003169 water-soluble polymer Polymers 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 1
- HTSVYUUXJSMGQC-UHFFFAOYSA-N 2-chloro-1,3,5-triazine Chemical compound ClC1=NC=NC=N1 HTSVYUUXJSMGQC-UHFFFAOYSA-N 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- MGNCLNQXLYJVJD-UHFFFAOYSA-N cyanuric chloride Chemical compound ClC1=NC(Cl)=NC(Cl)=N1 MGNCLNQXLYJVJD-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000004144 purine metabolism Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
Landscapes
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61093855A JPS6255079A (ja) | 1986-04-23 | 1986-04-23 | 修飾ウリカ−ゼ |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61093855A JPS6255079A (ja) | 1986-04-23 | 1986-04-23 | 修飾ウリカ−ゼ |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP4120379A Division JPS55135590A (en) | 1979-04-05 | 1979-04-05 | Modified asparaginase and uricase and their preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6255079A JPS6255079A (ja) | 1987-03-10 |
| JPH0126677B2 true JPH0126677B2 (enrdf_load_stackoverflow) | 1989-05-24 |
Family
ID=14094032
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP61093855A Granted JPS6255079A (ja) | 1986-04-23 | 1986-04-23 | 修飾ウリカ−ゼ |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS6255079A (enrdf_load_stackoverflow) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6136307A (en) | 1997-08-13 | 2000-10-24 | Oncolytics Biotech Inc. | Reovirus for the treatment of cellular proliferative disorders |
| CN1896231B (zh) | 1998-08-06 | 2012-09-05 | 山景药品公司 | 分离四聚体尿酸氧化酶的方法 |
| PL202799B1 (pl) * | 1998-08-06 | 2009-07-31 | Mountain View Pharmaceuticals | Sposób izolowania urykazy w postaci tetramerycznej oraz wyizolowana tetrameryczna urykaza |
| US6783965B1 (en) | 2000-02-10 | 2004-08-31 | Mountain View Pharmaceuticals, Inc. | Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates |
| US7229810B2 (en) | 2001-06-28 | 2007-06-12 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates of proteinases |
| MX2007012548A (es) | 2005-04-11 | 2008-03-11 | Savient Pharmaceuticals Inc | Formas variantes de urato oxidasa y uso de las mismas. |
| WO2008051178A2 (en) | 2006-04-12 | 2008-05-02 | Savient Pharmaceuticals, Inc. | Purification of proteins with cationic surfactant |
| US8148123B2 (en) | 2005-04-11 | 2012-04-03 | Savient Pharmaceuticals, Inc. | Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase |
| ES2538357T3 (es) | 2005-04-11 | 2015-06-19 | Crealta Pharmaceuticals Llc | Formas variantes de urato oxidasa y uso de las mismas |
| BRPI1010069A2 (pt) | 2009-06-25 | 2016-03-15 | Savient Pharmaceuticals Inc | "método para prevenir reações à infusão durante terapia por uricase peguilada em pacientes; e método para diagnosticar se um paciente tratado com uricase peguilada desenvolverá reações à infusão ou desenvolverá liberação de uricase peguilada mediada por anticorpo sem a medição de títulos de anticorpos anti-peg e anti-uricase peguilada" |
-
1986
- 1986-04-23 JP JP61093855A patent/JPS6255079A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS6255079A (ja) | 1987-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2398679C (en) | Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates | |
| KR100488848B1 (ko) | 피이지-유레이트 옥시데이즈 접합체 및 그의 이용 | |
| Anderson et al. | Kinetic properties of cyanase | |
| US20120149083A1 (en) | PEG-Urate Oxidase Conjugates and Use Thereof | |
| US6258774B1 (en) | Carrier for in vivo delivery of a therapeutic agent | |
| JPH0126677B2 (enrdf_load_stackoverflow) | ||
| AU2001249975A1 (en) | Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates | |
| CN106554948B (zh) | 突变型尿酸酶、peg修饰的突变型尿酸酶及其应用 | |
| CN111909906B (zh) | 聚乙二醇修饰的尿酸氧化酶 | |
| CN101875922B (zh) | 一种重组苛求芽孢杆菌胞内尿酸酶及其聚乙二醇修饰与应用 | |
| JP2012116840A (ja) | タンパク質ポリエチレングリコール（ｐｅｇ）複合体形成を増大させる方法 | |
| JP7689573B2 (ja) | ポリエチレングリコール修飾尿酸オキシダーゼの製造方法 | |
| Punnappuzha et al. | Synthesis and characterization of polysialic acid–Uricase conjugates for the treatment of Hyperuricemia | |
| Cai et al. | Characterization of the oxycomplex of lignin peroxidases from Phanerochaete chrysosporium: equilibrium and kinetics studies | |
| JPS6142558B2 (enrdf_load_stackoverflow) | ||
| JP6005732B2 (ja) | 非ペプチド性重合体−インスリン多量体及びその製造方法 | |
| WO2021246265A1 (ja) | Ｓ１００ａ８阻害ペプチドとこれを含む疾患治療薬 | |
| WO2025002334A1 (zh) | 尿酸氧化酶及其聚乙二醇化缀合物的稳定剂及其药物用途 | |
| HK1155203B (en) | Conjugates prepared with aggregate-free proteins | |
| HK1144701B (en) | Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates | |
| HK1155080A (en) | Isolated tetrameric uricase | |
| HK1143989B (en) | Conjugates prepared with aggregate-free proteins |